Biotesserae Camunity

What Biotesserae Camunity does

BioTesserae (also referenced as Biotesserae Camunity) is a private, early-stage for-profit company founded in 2016 and headquartered at HP Campus Building 11, 1110 NE Circle Blvd, Corvallis, Oregon. Per the firmographic data, the company develops a nanobody-based platform aimed at canine cancer treatments, positioning it within the veterinary biotechnology segment. The four co-founders — Chris Cebra, Dan Mourich, Carl Ruby, and Shay Bracha — constitute the core team, and the company operates with a headcount of 1-10 employees.

The company's commercial footprint is nascent. The only disclosed capital event is a $100,000 seed funding round led by Expert Dojo on January 6, 2022. No products, pricing models, customers, partnerships, certifications, patents, or product launches are documented in the available source material, and the website presents minimal product information beyond the platform framing. Operating status is described as active based on website presence and a working contact email ([email protected]), but no revenue, ARR, customer logos, or go-to-market mechanics are publicly disclosed.

Given the absence of pricing details, customer data, or partnership signals, the business model is not directly observable. The implied mechanics are those typical of a preclinical-stage veterinary biotech: non-dilutive grant funding, seed/angel capital, and eventual licensing or partnership with animal-health pharma companies, though none of these revenue channels are confirmed in the source data. Geographic scope is limited to a single U.S. site in Oregon, with no claimed international footprint.

Name

Biotesserae Camunity

Website

https://biotesserae.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

BioTesserae is an early-stage private veterinary biotech founded in 2016 in Corvallis, Oregon, developing a nanobody-based platform intended for canine cancer treatments and operating with a small founder-led team of under ten employees.

Ownership category

akta.pro rank

Product category

Veterinary Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Specialty Therapeutics (HLAMAEAJ)

akta.pro secondary industries

Companion Animal Therapeutics (Rx) (HLAMAEAA), Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK), Nanobodies & Alternative Antibody Scaffolds (HLAAAAAG)

Keywords

• Canine cancer therapeutics
• Nanobody platform
• Veterinary oncology
• Animal health biotechnology
• Canine immunotherapy

Headquarters

HQ city

Corvallis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

BioTesserae develops a proprietary nanobody-based platform for canine cancer treatments. The company leverages small antibody fragments (nanobodies) as the technological foundation to create targeted therapies intended for dogs suffering from cancer. The platform represents the company's core product focus within the veterinary oncology space.

Product overview

BioTesserae is a company based in Corvallis, Oregon. The source data provides limited information about the company's specific product offerings or service architecture. No detailed product descriptions, feature lists, or service modules were found in the available source material.

Differentiator

Problem solved

Functional benefit

Products and services

• Nanobody-based canine cancer therapeutics platform BioTesserae's proprietary nanobody-based platform designed to develop targeted therapeutics for canine cancer. The platform leverages small antibody fragments (nanobodies) as the technological foundation for treatments intended for dogs suffering from cancer.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Direct peers

• VetDC (now part of Elanco Animal Health): VetDC was a direct peer developing veterinary oncology therapeutics for canine cancer (notably Tanovea for lymphoma); it is now part of Elanco. It is the closest historical analog to a nanobody/canine cancer-focused startup and benchmarks the regulatory and commercial pathway BioTesserae would need to navigate.
• Aratana Therapeutics (historical, acquired by Elanco): Was a specialty veterinary therapeutics company developing innovative medicines for companion animals, including oncology. Its acquisition trajectory illustrates both the strategic value of canine specialty therapeutics and the consolidation pressure from major animal health players.

Broad incumbents

• Zoetis: The largest global animal health company, with an oncology franchise and broad veterinary biologic capabilities. Zoetis represents both a potential large exit partner and the dominant incumbent whose pipeline depth BioTesserae would have to differentiate against.
• Elanco Animal Health: Major animal health company that absorbed Aratana Therapeutics and VetDC, giving it a consolidated position in canine specialty therapeutics including oncology. Elanco is the most directly relevant incumbent in companion animal specialty pharma.
• Virbac: Global animal health company with a companion animal therapeutics portfolio spanning oncology, dermatology, and specialty care. Comparable as an established animal health player whose canine specialty footprint BioTesserae would need to compete with or partner into.
• Dechra Pharmaceuticals (acquired by Elanco): Was a leading specialty animal health company with deep companion animal therapeutics coverage prior to its acquisition by Elanco. Relevant as a comparable specialty vet therapeutics roll-up that illustrates consolidation dynamics in the space.

Emerging players

• argenx: Clinical-stage leader in nanobody therapeutics (efgartigimod in autoimmune disease). argenx validates the commercial and clinical potential of the nanobody modality that BioTesserae's platform is built on, and is the clearest read-across for platform value.
• AbCellera Biologics: Antibody discovery platform company using single-cell screening and AI to engineer therapeutic antibodies. It is a comparable platform-based biotech demonstrating how a discovery engine can be monetized via partnerships — a business model analogue for BioTesserae's platform.

Regional players

• Vetoquinol: Independent global animal health company with strong companion animal and equine therapeutic portfolios, particularly in Europe. Comparable as a mid-sized animal health player with companion animal specialty exposure and biologics/specialty franchises.

Others

• IDEXXX Laboratories: Although primarily a veterinary diagnostics company, IDEXX sits at the center of companion animal veterinary decision-making and is a likely downstream channel/partner for any novel canine oncology therapeutic entering clinical use.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/biotesserae

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotesserae Camunity